Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adrenomedullin and heart failure.

Miriam T Rademaker1, Vicky A Cameron, Christopher J Charles

  • 1The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand. miriam.rademaker@chmeds.ac.nz

Regulatory Peptides
|April 2, 2003
PubMed
Summary

Adrenomedullin (AM) is elevated in heart failure, predicting outcomes and identifying patients who benefit from carvedilol. AM administration improves heart function and renal function in heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Proteomic Signatures of Left Atrial Dysfunction and Cerebral Small Vessel Disease: Elucidating Heart-Brain Connections.

JACC. Basic to translational science·2026
Same author

Toll-like receptor 7 constrains efferocytosis in myocardial injury.

Basic research in cardiology·2026
Same author

Soluble urokinase plasminogen activator receptor for risk stratification from undifferentiated acute chest pain through to convalescence after acute coronary syndromes.

European heart journal open·2026
Same author

External Validation of a Universal Laboratory Pathway for Early Risk Stratification of Myocardial Infarction in the Emergency Setting.

The Canadian journal of cardiology·2026
Same author

Treatment of OSA using mandibular advancement versus CPAP in improving cardiovascular health.

The American journal of medicine·2026
Same author

Association of Left Ventricular Function With Cerebral Small Vessel Disease and Cognition.

Journal of the American Heart Association·2026

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Nephrology

Background:

  • Adrenomedullin (AM) is implicated in heart failure pathophysiology.
  • Elevated circulating AM correlates with cardiovascular disease severity and prognosticates adverse outcomes.
  • Raised AM levels in heart failure patients predict benefit from carvedilol therapy.

Purpose of the Study:

  • To investigate the role and therapeutic potential of adrenomedullin (AM) in heart failure.
  • To assess AM's prognostic value and its interaction with existing heart failure therapies.

Main Methods:

  • Analysis of circulating AM concentrations in cardiovascular disease patients.
  • Administration of AM in experimental and human heart failure models.
  • Evaluation of hemodynamic, renal, and hormonal responses to AM therapy.

Related Experiment Videos

  • Assessment of combined therapy effects (AM with ACE inhibitors and natriuretic peptides).

    • Main Results:

    • Elevated plasma AM levels in heart failure correlate with disease severity and predict adverse outcomes.
    • AM administration in heart failure reduces arterial and filling pressures, improving cardiac output.
    • AM inhibits aldosterone, sustains renal glomerular filtration, and promotes sodium excretion.
    • Combined AM therapy with ACE inhibitors and natriuretic peptides yields superior hemodynamic and renal benefits.

    Conclusions:

    • The adrenomedullin system is a promising therapeutic target for cardiovascular diseases, particularly heart failure.
    • AM has significant prognostic and therapeutic implications in managing heart failure patients.
    • Targeting the AM system offers a novel strategy for improving cardiovascular and renal function in heart failure.